

SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2006-08-03** | Period of Report: **2006-08-01**
SEC Accession No. **0000077551-06-000062**

([HTML Version](#) on secdatabase.com)

ISSUER

APPLERA CORP

CIK: **77551** | IRS No.: **061534213** | State of Incorporation: **DE** | Fiscal Year End: **0630**
SIC: **3826** Laboratory analytical instruments

Mailing Address
301 MERRITT 7
NORWALK CT 06851

Business Address
301 MERRITT 7
NORWALK CT 06851
2038402000

REPORTING OWNER

SLAYMAN CAROLYN W

CIK: **1200846**
Type: **4** | Act: **34** | File No.: **001-04389** | Film No.: **061001745**

Business Address
C/O APPLERA CORP
301 MERRITT 7
NORWALK CT 06856-5435
2038402000

FORM 4**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

OMB APPROVALOMB Number: 3235-0287
Expires: 02/28/2011
Estimated average burden
hours per response 0.5 Check this box if no longer
subject to Section 16. Form 4 or
Form 5 obligations may
continue. See Instruction 1(b).**STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of
the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment
Company Act of 1940

1. Name and Address of Reporting Person <u>SLAYMAN CAROLYN W</u>			2. Issuer Name and Ticker or Trading Symbol <u>APPLERA CORP [ABI/CRA]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>08/01/2006</u>					
<u>APPLERA CORPORATION, 301 MERRITT 7</u>			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person		
(Street) <u>NORWALK, CT 06851-1070</u>								
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Applied Biosystems Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		180	D	\$32.19	13,216	D	
Applied Biosystems Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		236	D	\$32.2	12,980	D	
Applied Biosystems Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		112	D	\$32.21	12,868	D	
Applied Biosystems Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		113	D	\$32.22	12,755	D	
Applied Biosystems Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		78	D	\$32.26	12,677	D	
Celera Genomics Group Common Stock Units								3,605.1	D	
Celera Genomics Group Common Stock	08/01/2006		<u>M</u>		1,500	A	\$5.0119	5,146	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		28	D	\$12.95	5,118	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		9	D	\$12.96	5,109	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		169	D	\$12.97	4,940	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		47	D	\$12.98	4,893	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		56	D	\$12.99	4,837	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		310	D	\$13	4,527	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾		38	D	\$13.01	4,489	D	

Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾	84	D	\$13.02	4,405	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾	56	D	\$13.03	4,349	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾	28	D	\$13.04	4,321	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾	309	D	\$13.05	4,012	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾	113	D	\$13.06	3,899	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾	84	D	\$13.07	3,815	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾	94	D	\$13.08	3,721	D	
Celera Genomics Group Common Stock	08/01/2006		<u>S</u> ⁽¹⁾	75	D	\$13.09	3,646	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

1. Reflects sale by independent third-party administrator under the issuer's Insider Diversification Program.

Remarks:

This is the second of two forms being filed by the reporting person on August 3, 2006.

Signatures

/s/ Thomas P. Livingston, Attorney-in-Fact for Carolyn W. Slayman

** Signature of Reporting Person

08/03/2006

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.